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Neurodegenerative dementias are a group of neurological disorders characterized by dete-
rioration in several cognitive domains in which there is selective and progressive loss of
speciﬁc populations of neurons.The precise neurobiological basis for the different neurode-
generative dementias remains unknown. It is expected that different pathologies reﬂect
different mechanisms, at least early in the neurodegeneration process. The next decades
promise treatments directed to causes andmechanisms, bringing an outstanding challenge
to clinicians due to heterogeneous clinical presentations with the same molecular pathol-
ogy. The purpose of this brief review is to describe the key neuropathological features
of the most common neurodegenerative dementias (Alzheimer disease, dementia with
Lewy bodies and Parkinson’s disease dementia, and frontotemporal lobar degeneration)
and the relationship with the clinical syndromes described in clinico-pathological studies.
We expect this overview contributes for the understanding of this broad topic integrating
the two ends of the spectrum: clinical and pathological.
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INTRODUCTION
Neurodegenerative dementias are a group of neurological disor-
ders characterized by deterioration in several cognitive domains
in which there is selective and progressive loss of speciﬁc popu-
lations of neurons (Dickson, 2011). The precise neurobiological
basis for the selective vulnerability in the different neurodegener-
ative dementias remains unknown. Furthermore, recent research
data showed that dementia is not only caused by “neuronal cell
death”/cell loss but predominantly by dysfunction and loss of
synapses in Alzheimer disease and in dementia with Lewy bod-
ies (DLB; Jellinger, 2009). These changes cause disconnections of
important nervous circuitries which can contribute to the clinical
manifestations. An increasing number of hypotheses to explain
the pathogenesis of Alzheimer’s disease, for instance, have been
proposed but it remains a mystery a century after this demen-
tia was ﬁrst described (de la Torre, 2011). In the most common
neurodegenerative disorders there are biochemical changes in a
speciﬁc protein that often promotes their deposition (Dickson,
2010). Over the last decade, many researchers have investigated
the neuropathological background of the phenotypic variability
in neurodegenerative dementia and identiﬁed a wide spectrum of
associations between clinical syndromes and molecular patholo-
gies. The classiﬁcation of neurodegenerative diseases, previously
based on the anatomical systems involved, has been progressively
replaced by molecular diagnosis (Jellinger and Kovacs, 2011b).
Thenext decades promise treatments that are directed at chang-
ing pathogenesis, increasing the importance for clinicians’ aware-
ness of the full clinical spectrum under the umbrella of the same
molecular pathology.
The purpose of this brief review is to describe the key neu-
ropathological features of the most common neurodegenerative
dementias [Alzheimer’s disease, DLB and Parkinson’s disease
dementia (PDD),and frontotemporal lobar degeneration (FTLD)]
and the relationship with the clinical syndromes described in
clinico-pathological studies.
ALZHEIMER DISEASE
Alzheimer’s disease (AD) is the most frequent cause of dementia
worldwide, and its prevalence increases steeply after age 65 years,
representing a signiﬁcant health-care cost in developed coun-
tries (Reitz et al., 2011). Despite signiﬁcant advances have been
made in the understanding of AD pathogenesis, it remains largely
unknown. Monogenic causes of familial early onset AD include
autosomal dominant mutations in the β-amyloid precursor pro-
tein (APP), presenilin 1, and presenilin 2 protein genes, but rep-
resent less than 5% of AD cases (Bertram, 2008). Together with
identiﬁcation of apolipoprotein E ε4 allele as a genetic risk fac-
tor for late onset AD (Saunders et al., 1993) and neuropathology
ﬁndings (see below), this evidence supports the amyloid cas-
cade hypothesis as an important contributor in AD pathogenesis
(Hardy and Higgins, 1992), even though other converging mecha-
nismsmost certainly play important roles innon-Mendelian forms
of AD. More recently, genome-wide association studies have iden-
tiﬁed multiple genetic polymorphisms which are associated with
late onset, non-Mendelian AD, and suggest involvement of other
molecular pathways, namely implicating immune system, synap-
tic, and cell membrane function (Bertram, 2011; Morgan, 2011).
AD pathogenesis theories must also recognize contribution of
environmental factors, since several risk factors and modiﬁers of
disease expression such as age (Ferri et al., 2005), cognitive reserve
(Roe et al., 2007), physical activity (Podewils et al., 2005), smoking
(Anstey et al., 2007), obesity (Lee, 2011), diabetes (Biessels et al.,
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2006), and intracranial atherosclerosis (Dolan et al., 2010) have
been found. Core classical clinical characteristics of AD include
a gradual and progressive decline of cognitive function which
affects episodic memory, involves other cognitive domains, and is
not explained by other medical or psychiatric conditions. Several
diagnostic criteria have been proposed, namely the National Insti-
tute of Neurological Disorders and Stroke–Alzheimer Disease and
Related Disorders criteria (McKhann et al., 1984), and the Diag-
nostic and Statistical Manual of Mental Disorders fourth edition
criteria (American Psychiatric Association, 2000), but increasing
evidence concerning magnetic resonance imaging (MRI), cere-
brospinal ﬂuid (CSF), and functional neuroimaging ﬁndings has
led to a new proposal of research criteria for the diagnosis of AD
(Dubois et al., 2007), in which is implied a reformulation of clas-
sic concepts in AD and mild cognitive impairment (Dubois et al.,
2010). In all these criteria, neuropathological ﬁndings consistent
with AD are required for a deﬁnite diagnosis, since it is assumed
that a clinical diagnosis, even though may have high accuracy, is
probabilistic.
PATHOLOGY
Brain pathology abnormalities inADmaybe classiﬁed as“positive”
or accumulation lesions (Aβpeptidedeposits and tauprotein accu-
mulation), “negative” lesions (neuronal loss, loss of synapses), or
a third type of lesion which include dendritic and axonal changes
and inﬂammatory reaction lesions (Gomez-Isla et al., 2008).
Aβ peptide is cleaved from APP by β-secretase and γ-secretase
enzyme complexes, and it is accumulated in AD, taking the form
of mature neuritic plaques (senile plaques) or different types of
extracellular deposits in brain parenchyma (Figures 1A–C). Neu-
ritic plaques, stained by Congo red, are complex lesions formed
by extracellular focal deposits of Aβ, neuronal processes (axonal
or dendritic), microglial cells, and astrocytic processes (Duyck-
aerts et al., 2009). Neuritic plaques are found evenly distributed
through the isocortex, preferentially in layers II and III, with high
density in associative cortices, are relatively sparse in hippocampal
and parahippocampal areas and are nearly absent in striatum and
presubiculum (Duyckaerts and Hauw, 1997). Diffuse Aβ deposits
are weakly immunoreactive and may be found in speciﬁc regions,
such as the presubiculum (Wisniewski et al., 1998) and entorhinal
cortex (Thal et al., 1999). Other focal and stellate Aβ deposits were
also described, with different distributions through the cortical
layers (Delaère et al., 1991). In 1991, the Consortium to establish
a registry for AD (CERAD) established a neuropathologic method
for diagnosing “deﬁnite,” “probable,” or “possible” AD, primarily
based on a semiquantitative assessment of the number of neuritic
plaques and its correlation with age (Mirra et al., 1991).
In AD, tau protein accumulation (three repeat and four repeat
isoforms) takes the formof neuroﬁbrillary tangles (cell body),neu-
ropile threads (dendrites), and is also identiﬁed in the corona of
neuritic plaques (Figures 1C,D). Neuroﬁbrillary tangles, ﬂame-,
or globose-shaped silver positive intracellular inclusions, tend
to accumulate in the entorhinal cortex, hippocampus, amygdala,
basal nucleus of Meynert, and layers III andV of the isocortex, pre-
dominantly affecting neurons responsible for cortico-cortical pro-
jections (Arnold et al., 1991). Neuropil threads represent swollen
dendrites with tau accumulation, occur in the same topography as
FIGURE 1 | Alzheimer’s disease neuropathology. (A) Senile plaque
(hematoxylin–eosin) with amyloid core (arrow ). (B) Senile plaques with
anti-Aβ antibody. The amyloid core (arrow ) is surrounded by a corona of
lightly labeled Aβ peptide. Arrowhead indicates vascular amyloid deposition
in a capillary (Cambridge Bioscience, 4G8). (C) Neuritic plaques
immunostained with tau antibody.The arrow indicate the core of the plaque
and arrowhead the tau-positive processes of the neuritic crown (inset). (D)
Flame-shaped neuroﬁbrillary tangles. Inset shows a globose neuroﬁbrillary
tangle (Autogen Bioclear, AT8). Magniﬁcation, 400× (A), 100× (B,C), and
200× (D).
neuroﬁbrillary tangles and predominate in the earlier stages of the
disease (Giannakopoulos et al., 2007). The neuritic plaque is where
amyloid and tau pathology coincide, since the dystrophic large
axonal processes in the corona at the periphery of the plaque core
are tau-positive (Wang and Munoz, 1995). Despite the classical
hypothesis that amyloid deposition drives the disease, neuroﬁb-
rillary tangles have been shown to occur before amyloid lesions
(Braak and Tredici, 2004), which highlights the poor understand-
ing of tau–amyloid relationship, and of the role of other factors in
AD pathogenesis. Braak and Braak (1991) proposed six stages for
AD neuropathology, based on distribution and severity of neu-
roﬁbrillary tangle pathology, and it has been demonstrated that
these stages are closely related to clinical symptoms and dete-
rioration (Riley et al., 2002). Interestingly, progression of tau
pathology through a relatively predictable topography, a process
which underlies progression of clinical symptoms, may result
from a prion-like mechanism of neuron to neuron propagation
of pathology (Braak and Tredici, 2011).
Neuronal loss is possibly the most signiﬁcant microscopic cor-
relate of gross macroscopic cerebral atrophy in patients with AD,
occurring markedly in layer II of entorhinal cortex even in early
clinical phases (Gomez-Isla et al., 1996), CA1, superior temporal
gyrus, and supramarginal gyrus (Grignon et al., 1998).
Synaptic loss is reported to be an early event in the neurode-
generative process occurring in AD, and it is thought to be the
major correlate of cognitive decline (Arendt, 2009). Distribution
and degree of synapse degeneration is coincident with neuroﬁb-
rillary tangle accumulation, suggesting a link between tangles and
loss of synapse markers (Callahan et al., 1999).
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Other neuropathology ﬁndings include local spine loss, axonal
swellings, dysmorphic neurites, aberrant dendritic sprouting,
inﬂammatory changes with activated microglia, astrocytosis,
spongiosis, and Lewy bodies (LBs; Duyckaerts et al., 2009).
Recently, a new and comprehensive proposal for the neu-
ropathological evaluation of AD was proposed by the National
Institute on Aging-Alzheimer’s Association, in which there is
emphasis on identiﬁcation of amyloid deposits, staging of neu-
roﬁbrillary tangles, scoring of neuritic plaques, and system-
atic search for other neurodegenerative dementia pathologies
(Montine et al., 2012).
CLINICO-PATHOLOGICAL CORRELATIONS
Classical AD clinical phenotype is characterized by: (1) decline
from a previous level of function; (2) interference in daily living,
work, and social interaction; (3) cognitive impairment with signif-
icant emphasis on episodic memory, accompanied by progressive
and increasing involvement of other cognitive domains (visu-
ospatial function, executive skills, attention, praxis, language);
(4) progressive behavioral deterioration (depressive symptoms,
disruptive behavior, apathy, anxiety, psychosis). This typical phe-
notype is the basis for the currently accepted diagnostic criteria.
Clinical NINCDS-ADRDA criteria for AD has a reasonable sensi-
bility and speciﬁcity for differentiating AD from normal controls,
but accuracy for the differential diagnosis of neurodegenerative
dementias may be very low (Ballard et al., 2011). The most recent
research criteria for diagnosing AD (Dubois et al., 2007) have not
been validated and there is debate on which neurocognitive tests
should be used for characterization and quantiﬁcation of cognitive
deﬁcits, and which are the best auxiliary biomarkers, deﬁnition
of their pathological threshold and their clinical value in single
patients (Oksengard et al., 2010).
Growing evidence from neuropathologic studies and new
in vivo biomarkers allowed for identiﬁcation and further char-
acterization of atypical or focal presentations of AD and also an
increased understanding about other neurodegenerative demen-
tias. AD atypical presentations include posterior cortical atro-
phy (PCA), primary progressive aphasias (PPA), corticobasal
syndrome (CBS), and frontal lobe syndrome (FLS).
Posterior cortical atrophy was ﬁrst identiﬁed by Benson et al.
(1998). Clinical phenotype is characterized by a progressive dete-
rioration in complex visual functions, leading to a perceptual
agnosia, Bálint syndrome, Gerstmann syndrome, and ultimately
visual ﬁeld defects, with no or residual impairment of other cog-
nitive functions at least in early stages. Neuropathological studies
support the hypothesis of dysfunction of the dorsal occipito-
parietal visual pathway, and in the majority, AD pathology is
found. Some studies have found a characteristic distribution of
neuritic plaques and neuroﬁbrillary tangles, with antero-posterior
gradient in occipito-parietal regions (lower density in primary
visual cortex), and relative sparing of frontal cortex (Levine et al.,
1993; Hof et al., 1997). When comparing PCA and typical AD
phenotype, it was found that the former had higher density of
neuritic plaques and neuroﬁbrillary tangles in visual association
cortex and the later had higher density of lesions in hippocam-
pus and subiculum, but there were no differences in other cortical
areas (Tang-Wai et al., 2004). Clinical progression may disclose
clues to underlying pathology: development of episodic memory
impairment and involvement of other cognitive domains sug-
gests AD; visual hallucinations, delusions, and parkinsonism may
indicate DLB; asymmetric parkinsonism and ideomotor apraxia
may suggest corticobasal degeneration, CBD; rapid progression
of global disability, myoclonus, and cortical blindness with Anton
syndrome suggest prion disease (namely the Heidenhain variant
of Creutzfeldt–Jakob disease). It should be noted, however, that
despite the etiological diversity of PCA, in over 75% of cases, AD
pathology was shown (Renner et al., 2004; Tang-Wai et al., 2004).
Clinically, PPA may be subclassiﬁed in logopenic progressive
aphasia (LPA; slow speech, impaired word retrieval, compre-
hension, and repetition), progressive non-ﬂuent aphasia (PNFA;
effortful speech, agrammatism, speech apraxia, dysprosody), and
semantic dementia (SD; ﬂuent, impaired confrontation naming,
and word comprehension, surface dyslexia; Gorno-Tempini et al.,
2011). LPA is the PPA subtype more strongly correlated with
AD. Mesulam et al. (2008) found AD pathology in 7/11 patients
with LPA. Even though LPA patients show atrophy in left poste-
rior temporal and inferior parietal regions (Gorno-Tempini et al.,
2008), distribution of neuroﬁbrillary tangles did not show con-
sistent hemispheric asymmetry in PPA/AD patients when using
the CERAD protocol, while a stereological tangle quantiﬁcation
in four PPA/AD cases revealed higher tangle density in left hemi-
sphere and similar entorhinal tangle density as typical AD cases
(Mesulam et al., 2008). PNFA is classically associated with tau
pathology but a signiﬁcant proportion of patients who have come
to autopsy haveAD pathology (Grossman, 2010), and atypical dis-
tribution of lesions was described,with prominent involvement of
left anterior perisylvian regions (Greene et al., 1996). SD is char-
acteristically associated with TAR DNA binding protein (TDP)
pathology (Seelaar et al., 2011), but 2/20 patients with SD had
neuropathologic ﬁndings of AD (Alladi et al., 2007), and among
15 patients with ﬂuent progressive aphasia, 33% had AD pathol-
ogy,with striking atrophy and extensive neuritic plaque and tangle
deposition in left anterior temporal and frontal lobes (Knibb et al.,
2006).
Corticobasal syndrome is characterized by a slowly progres-
sive constellation of manifestations which include asymmetric
parkinsonism, asymmetric apraxia, unilateral useless limb, alien
hand syndrome, cortical sensory loss, action myoclonus, and visu-
ospatial deﬁcits. It is now known that CBS is a neuropathological
heterogeneous entity, and AD pathology was shown to be present
in 24–50% in autopsy studies. Visual neglect, visual memory
impairment, episodic memory deﬁcits, and posterior extension
of atrophy into precuneus and temporoparietal cortex are possi-
ble clinical indicators of CBS/AD (Alladi et al., 2007; Ling et al.,
2010; Lee et al., 2011b).
Frontal lobe syndrome is dominated by deterioration of frontal
functions, with dysexecutive syndrome, apathy, or disinhibition,
changes in behavior, and social interaction. Initially, episodic
memory impairment is absent or residual (Taylor et al., 2008),
but usually progresses. Compared to typical AD, FLS/AD patients
were reported to have greater impairment in Trail Making Test,
phonemic ﬂuency, and visuoconstructive skills (Johnson et al.,
1999). In the previously mentioned cohort of focal dementia
syndromes, among 28 patients with FLS, two had pathological
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ﬁndings consistent with AD (Alladi et al., 2007). In terms of
neuroﬁbrillary tangle load, entorhinal, temporal, and parietal cor-
tex in typical AD is similar to FLS/AD, but the later have a signiﬁ-
cantly higher tangle density in frontal cortex (Johnson et al., 1999).
No β-amyloid pathology distribution differences were found in
this study.
In summary,AD pathology is associated principally to the clas-
sical clinical phenotype of Alzheimer’s disease with loss of episodic
memory, but it should be noted that focal presentations of AD are
part of the spectrum of the AD pathology (i.e., PCA, PPA, CBS,
and FLS).
PARKINSON’S DISEASE DEMENTIA AND DEMENTIA WITH
LEWY BODIES
Parkinson disease dementia and DLB represent two clinical phe-
notypes of the neurodegenerative dementia disorders diagnosed
by the presence of LBs and Lewy neurites (LN).
Parkinson’s disease (PD) is one of the most frequent neurode-
generative diseases of the elderly. It is characterized clinically by
bradykinesia, rigidity, resting tremor, and postural instability. The
clinical diagnostic criteria require the presence of two of the four
cardinal signs that are responsive to levodopa therapy (Gelb et al.,
1999). The diagnosis of deﬁnitive PD requires histopathological
conﬁrmation, namely the presence of LBs in association with loss
of substantia nigra neurons (Dickson et al., 2009). Clinical cohorts
of patients identiﬁed with early PD are heterogeneous when refer-
ring to symptoms (resting tremor vs. akinesia and rigidity and/or
postural instability and gait disorder), rates of progression (rapid
vs. slow), and ages of onset (early vs. late onset), often with over-
lap between these phenotypes (Halliday and McCann, 2010). The
prevalence of dementia in PD (i.e., PDD) is close to 30% and
at least 75% of PD patients who survive for more than 10 years
will develop dementia (Aarsland et al., 2005; Aarsland and Kurz,
2010). Age is an essential factor, and dementia is infrequent in
patients with young onset and who are chronologically still young
at the time of assessment, despite very long disease duration.
The principal risk factors are older age, more severe parkinson-
ism (rigidity, postural instability, and gait disturbance), and mild
cognitive impairment at baseline (Emre et al., 2007).
Dementia with Lewy bodies is considered to be the secondmost
common type of degenerative dementia in the elderly, accounting
for 10–15% of cases at autopsy (McKeith et al., 1996). Clinically
it is characterized by prominent visuoconstructive and frontal-
subcortical impairment, associated with core clinical neuropsy-
chiatric features of ﬂuctuating cognitive function, visual hallu-
cinations, and spontaneous parkinsonian motor signs (McKeith
et al., 2004, 2005). Both conditions have been associated to higher
rates and more severe depression when compared to AD (Fritze
et al., 2011).
For research purposes an arbitrary cut-off of 1 year is used to
distinguish PDD from DLB. When PD develops ﬁrst and demen-
tia develops 1 year or more lately the diagnosis of PDD is made, if
the cognitive impairment precedes motor symptoms or develops
earlier the diagnosis is of DLB (Lippa et al., 2007).
There are no deﬁnite pathological criteria that separate the two
disorders (Lippa et al., 2007) and the separation between PDD and
DLB is considered by some to be artiﬁcial (Halliday et al., 2011).
PATHOLOGY
There is no “gold standard” for the pathological diagnosis of
DLB or PDD. The hallmark pathology is α-synuclein (αSyn) in
form of LBs (both classical and cortical types) and LN (Halli-
day et al., 2011; Ince, 2011). Classical LBs (Figure 2A) are easily
recognizable by standard histological methods as large, spheri-
cal, highly eosinophilic intracytoplasmatic inclusions with a clear
halo in the dopaminergic neurons of substantia nigra and the
locus coeruleus (McKeith et al., 1996; Kövari et al., 2009). Cor-
tical LBs (Figures 2B,C) are seen in limbic and neocortical
regions, predominantly in the small neurons of deep layers of
the cortex. Because of their small size they are easily identiﬁed
using immunohistochemistrywithαSyn antibodies (Figures 2E,F;
Kövari et al., 2009). LN are curvilinear or dot-like processes
(Figures 2D–F) that are found in regions with the highest den-
sity of LBs, such as limbic cortex and amygdala (Saito et al., 2003;
Dickson, 2010).
In spite of being the hallmark of DLB and PD, LBs they can
be detected in the amygdala in up to 50% of patients with clin-
ically and pathologically conﬁrmed AD (Hamilton, 2000) and in
up to 10% of neurologically normal elderly individuals over age of
60 years (Gibb and Lees, 1998). α-synuclein is a small, presynap-
tic protein without a well-deﬁned function. Some data implicate
the misfolding or aggregation of αSyn in the disease pathogenesis,
but the mechanisms that underlie the aberrant functions of α-
synuclein and how these impacts on disease pathogenesis remain
poorly understood (Forman et al., 2004; Vekrellis et al., 2011).
CLINICO-PATHOLOGICAL CORRELATIONS
A staging system, based on the number and location of LBs, with
a caudal to rostral six-stage progression has been proposed for
sporadic PD (Braak et al., 2003). The ﬁrst two stages, with LB
pathology involving medulla oblongata and pontine tegmentum,
are considered asymptomatic or presymptomatic and may explain
the early non-motor symptoms (autonomic and olfactory). Stages
3 and 4, with extension of LB pathology to midbrain and basal
prosencephalon and mesocortex, have been correlated to clinical
symptomatic stages. The terminal stages 5 and 6, characterized
by widespread neocortical LB degeneration, are correlated with
signiﬁcant cognitive decline associated with severe parkinsonism
(Hurtig et al., 2000). Although there is an acceptable correlation
between pathological ﬁndings and clinical data in this staging
system, mainly in a subgroup with early onset and prolonged
duration (Halliday et al., 2008), recent studies revealed exceptions
to the general order of progression suggested by Braak and col-
leagues (Jellinger, 2008; Parkkinen et al., 2008;Dickson et al., 2009;
Kalaitzakis et al., 2009). Another interesting observation from a
number of recent clinico-pathological studies that assessed the
progression of pathology in subtypes of PD is that in patients with
non-tremor-dominant and postural instability and gait dominant
clinical pictures there are signiﬁcantly more cortical LBs and amy-
loid β plaques compared with tremor dominant or younger onset
patients (Selikhova et al., 2009;Halliday et al., 2011). Furthermore,
PD patients with dementia have higher amounts of cortical αSyn
pathology as compared to those without dementia and a correla-
tion between its severity and AD pathology is also present in such
patients (Halliday et al., 2011).
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FIGURE 2 | Dementia with Lewy bodies neuropathology. Lewy body in a
neuron of the substantia nigra (A), in a pyramidal cell of CA1 area of the
hippocampus (B), and in cingulated cortex (C) (arrows). Lewy body (arrow )
and Lewy neurites (arrowheads) in the substantia nigra (D). Cortical Lewy
bodies (E,F). (A–C) hematoxylin–eosin; (D–F) anti-α-synuclein
immunostaining. Magniﬁcation, 400× (A–C,F) and 200× (E).
According to the consensus pathologic guidelines for DLB,
LBs are scored semiquantitatively according to the severity and
anatomical distribution, separating brainstem-predominant, lim-
bic (or transitional), and neocortical types, depending on the
anatomical distribution of the αSyn pathology (McKeith et al.,
1996, 2005). More recently, a new protocol for assessing αSyn
pathology and currently recommended by the DLB Consortium,
showed higher inter-observer agreement for both the assignment
to brainstem, limbic, neocortical and amygdala-predominant cat-
egories of synucleinopathy, and Braak stages (1–6; Alafuzoff
et al., 2009). Alzheimer’s disease pathology is the most common
co-occurring pathology that accompanies Lewy body pathology
(PDD or DLB; Dickson et al., 2009) and most cases with cortical
LBs show in some degree concomitant AD pathology (i.e., NFTs
and neuritic plaques; Kövari et al., 2009). The methods proposed
by the third Consortium for DLB (McKeith et al., 2005) recom-
mend the description of Alzheimer disease-type pathology using
the National Institute on Aging-Reagan Institute criteria (Hyman
and Trojanowski, 1997). It is proposed that the DLB clinical syn-
drome is directly related to the severity of Lewy-related pathology,
and inversely related to the severity of concurrentAD-type pathol-
ogy (McKeith et al., 2005). In cases of “pure” DLB (i.e., without
excessive tau neuritic pathology) clinical picture appears more
similar to the dementia phenotype of PD than to AD (Emre et al.,
2007). There is evidence suggesting that the increase of neocortical
αSyn is associated with cognitive decline in DLB and PD (Hurtig
et al., 2000;Kövari et al., 2003) and some clinico-pathological stud-
ies demonstrated that visual hallucinations are strongly related to
the αSyn burden in the amygdala in both (Casanova et al., 2011).
Within the DLB phenotype spectrum, some clinico-
pathological studies and case reports disclose a subset of DLB
patients with rapid symptoms progression to death within 1–
2 years (Armstrong et al., 1991; Haik et al., 2000). These patients
can fall within the differential diagnosis of rapid progressive
dementias such as Creutzfeldt–Jakob disease, andmore recent data
show that 7–10% of autopsy conﬁrmed diffuse Lewy body disor-
der cases can have a rapid PD and dementia progression (Gaig
et al., 2011; Jellinger and Attems, 2011a). The neuropathology of
these cases did not show particular features that could differentiate
rapidly progressing from classical forms.
In summary, PDD and DLB refers to a form of dementia
that has the pathological signature of abnormal aggregates of α-
synuclein in the form of LBs and LN. There is a considerable
clinical heterogeneity explained, at least partially, by topographic
distribution of αSyn aggregates and the presence of additional
neuropathologies such as AD pathology. In fact, large autopsy
series show that although the speciﬁcity of ante-mortem diagno-
sis of DLB when correlated to pathological diagnosis was over
95%, the sensitivity of the clinical diagnoses was quite low (32%).
Furthermore, these studies show that that in late-stage cognitive
impairment, speciﬁcally documented signs and symptoms asso-
ciated with DLB (visual hallucinations, extrapyramidal signs, and
ﬂuctuating cognition) do not contribute for predicting the pres-
ence of neocortical LBs at autopsy. Consequently, while these
clinical symptoms may be useful in milder cases of dementia, cau-
tion should be used when providing a diagnosis of LBD in patients
with more advanced dementia (Nelson et al., 2010).
FRONTOTEMPORAL LOBAR DEGENERATION
Frontotemporal lobar degeneration refers to a clinical, genetic,
and pathological heterogeneous group of disorders that constitute
a common cause of dementia with onset usually before 65 years
of age (Cairns et al., 2007; Pickering-Brown et al., 2008). FTLD
is a macro-anatomical descriptive term reﬂecting the relatively
selective involvement of frontal and temporal lobes that charac-
terizes most cases (Rohrer et al., 2011). Epidemiological studies
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suggest that FTLD is the second most common cause of young
onset dementia afterAD (Ratnavalli et al., 2002; Rosso et al., 2003).
The clinical spectrum of FTLD encompasses three canonical syn-
dromes that are distinguished by the presenting symptoms and
regional pattern of atrophy: the behavioral variant frontotempo-
ral dementia (bvFTD), with predominant behavioral symptoms;
PNFA, a disorder of expressive language; and SD, a disorder of
conceptual knowledge (Neary et al., 1998; Kertesz et al., 1999,
2005). There is also overlap of FTLD with motor neuron disease
(FTD–MND), as well as the parkinsonian syndromes progressive
supranuclear palsy and CBD (Litvan et al., 1996; Neary et al., 1998;
Boeve et al., 2003).
A positive family history is common in FTLD, with up to 40%
cases showing a pattern of inheritance consistent with autosomal
dominant transmission of disease (Neary et al., 2005; Seelaar et al.,
2011). Genetic heterogeneity of FTLD is reﬂected by the identi-
ﬁcation of seven different genes that are associated with FTLD.
Mutations in genes encoding for microtubule-associated protein
tau (MAPT) and progranulin (GRN ) are responsible for approx-
imately 50% of the familial cases, where other genes associated
with FTLD pathology are extremely rare and include mutations
in the valosin-containing protein (VCP) gene, the charged multi-
vesicular body protein 2B (CHMP2B) gene, the TAR DNA binding
protein 43 (TARDBP) gene and the fused in sarcoma (FUS) gene
(Josephs et al., 2011; Seelaar et al., 2011). More recently, an expan-
sion in chromosome 9 (C9ORF72 gene) was identiﬁed as cause
of Chromosome 9p21-Linked FTD–MND (DeJesus-Hernandez
et al., 2011; Renton et al., 2011).
PATHOLOGY
The pathology of the group of disorders under the FTLD umbrella
term overlaps in gross and histological features. All share the
ﬁndings of selective atrophy of the frontal and temporal cor-
tex (Figure 3), with neuronal loss, gliosis and spongiosis of the
superﬁcial layers, especially of layer II. In some patients there is
asymmetry of atrophy, typically reﬂected in perisylvian loss on
one side of the brain. Speciﬁc diagnosis of the neurodegenerative
disease within the FTLD group is established by the identiﬁcation
of the protein that constitutes the cellular inclusions (Cairns et al.,
2007). Three proteins have been identiﬁed as important players
in the mechanism of neurodegeneration of the FTLD: MAPT, the
transactive responseDNAbinding protein of 43 kD (TDP-43), and
the tumor associated protein FUS (Josephs et al., 2011). Therefore,
the majority of FTLDs can be subclassiﬁed at molecular level as
FTLD–tau, FTLD–TDP, and FTLD–FUS (Mackenzie et al., 2010a).
However, the exact mechanisms by which cell death occurs are not
known.Wewill use this subclassiﬁcation to characterize further the
pathology features within each subgroup and, in the next section,
to serve as basis for the clinico-pathological correlates reported in
the literature.
FTLD–tau
In this group the major abnormal protein identiﬁed by immuno-
histochemistry is the tauprotein.This group includesPick’s disease
(Dickson, 2001) and the pathological entities CBD and progressive
nuclear palsy, which can fall under the FTLD clinical presentation
(Litvan et al., 1996; Boeve et al., 2003;Kertesz, 2003; Scaravilli et al.,
FIGURE 3 | Macroscopical findings of a FTLD–TDP brain. Lateral (A) and
medial view (B) showing cortical atrophy that involves frontal, temporal, and
parietal lobes, with better preserved sensorimotor cortex and occipital lobe.
2005; Josephs et al., 2006). Tau is a phosphoprotein that promotes
microtubule polymerization and stabilization. The discovery of
multiplemutations in the tau gene that lead to the abnormal aggre-
gation of tau and cause FTLD demonstrates that tau dysfunction
is sufﬁcient to produce neurodegenerative disease, but the precise
mechanisms remain to be completely elucidated (Lee et al., 2001).
The microtubule binding domain of the tau protein contains three
of four repeat regions (tau 3R and 4R) depending on the splicing
of the RNA. There is preferential accumulation of 3R or 4R tau in
the different tauopathies, allowing a biochemical subclassiﬁcation
within this group.
In Pick’s disease (PiD), the most characteristic neuropatho-
logical feature is the presence of Pick bodies. Pick bodies are
spherical cytoplasmatic neuronal inclusions, that are well demar-
cated, amorphous, and faintly basophilic on hematoxylin–eosin
staining (Figures 4A,B). They are strongly argyrophilic but do not
stain with Gallyas (Dickson et al., 2011b). They are abundant in
the dentate gyrus of the hippocampus and also common on the
cerebral cortex,particularly in layers II and III (Munoz et al., 2011).
Pick bodies contain deposition of tau protein (Figures 4C,D)
that is abnormally hyperphosphorylated and biochemistry analy-
sis showed that most of the tau consists of 3R tau (Delacorte et al.,
1998; Bronner et al., 2005). Mutations in the tau gene (MAPT ),
most commonly associated to bvFTD-like phenotype in which
extrapyramidal features may also be present (Josephs et al., 2011),
account for the most pathologically conﬁrmed cases of familial
PiD (Dickson et al., 2011b). The neuropathological characteris-
tics associated to MAPT gene mutations vary substantially, but
the hallmark is the presence of tau protein deposits in neurons
and/or glia (Ghetti et al., 2011). The pathology can resemble other
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FIGURE 4 | Neuropathology of Pick’s disease. Pick bodies (arrows) in frontal cortex. (A,B) Hematoxylin–eosin; (C,D) tau immunostaining. Magniﬁcation,
1000× (A–C), 400× (D).
tauopathies as PiD, PSP, or CBD and, for instances, neuropatho-
logical criteria for CBD states that for differentiate it from MAPT
gene mutation cases additional clinical or molecular genetic infor-
mation is required to make an accurate diagnosis (Dickson et al.,
2002).
Corticobasal degeneration, as a pathological entity, is associ-
ated to a wide range of clinical presentations (see below). CBD is a
4R tauopathy (Dickson et al., 2011b). The characteristic pathology
in CBD is tau immunoreactive inclusions in the cell processes of
neurons and glia in the cortex, basal ganglia, thalamus, and brain-
stem. Tau-reactive thin, thread-like processes of glial and neuronal
origin are also seen throughout the gray and white matter and are
an important feature of the pathology of CBD. The most speciﬁc
histopathological lesion in CBD is the astrocytic plaque, a distinc-
tive annular cluster of thick, short tau immunoreactive deposits
within the distal processes of astrocytes (Dickson et al., 2002).
Ballooned neurons, described since the ﬁrst report of the disease
under the name“corticodentatonigral degenerationwith neuronal
achromasia” (Rebeiz et al., 1967), are swollen cortical neurons,
eosinophilic in hematoxylin–eosin staining, most often found in
the third, ﬁfth, and sixth cortical layers. They are immunoreac-
tive to phosphorylated neuroﬁlaments and alpha–beta-crystallin
(Dickson et al., 2002). Despite of being one of the histological hall-
marks of CBD, this type of neuronal degeneration itself is known
to be a non-speciﬁc change and can be seen in other pathological
conditions (Ikeda, 1997).
Progressive supranuclear palsy is also a 4R tauopathy. The most
characteristic neuronal lesion on histopathology is the globose
neuroﬁbrillary tangle, while the most signiﬁcant astrocytic lesion
is the tufted astrocyte (Nishimura et al., 1992;Yamada et al., 1992),
characterized by a tuft like arrangement of cell processes around
the astrocyte cell body. They are both best appreciatedwithGallyas
silver stain or tau immunohistochemistry. The core neuroanatom-
ical regions affected include basal ganglia, subthalamic nucleus,
and substantia nigra, with cortical involvement more pronounced
in motor and premotor cortices (Dickson et al., 2011b). Neu-
ropathological criteria for PSP are based on the distribution of
tau pathology and the exclusion of other neurodegenerative dis-
orders associated to parkinsonism and dementia (Hauw et al.,
1994). However, these criteria did not take into account the atyp-
ical clinical PSP presentations that can present under the FTLD
spectrum.
FTLD–TDP
In this group the pathological changes signature consists in
the presence of immunoreactive TDP-43 neuronal cytoplasmatic
inclusions (NCI), dystrophic neurites (DN), and in some cases
neuronal intranuclear inclusions (NII) in the frontotemporal neo-
cortex and dentate granule cells of the hippocampus (Figure 5;
Neumann et al., 2006; Davidson et al., 2007). TDP-43 is a ubiqui-
tously expressed, highly conserved nuclear protein that regulates
RNA in a variety of ways. Converging lines of research sug-
gest that TDP-43 is mechanistically linked to neurodegeneration,
with many pathways probably involved, including gain of toxic
functions and loss of normal functions (Lee et al., 2011a). Four
subtypes of FTLD–TDP are currently recognized based on mor-
phology and anatomical distribution of TDP-43 lesions (Macken-
zie et al., 2011a). Type A is characterized by numerous short DN
and crescentic or oval NCI, as well as moderate numbers of NII
(Figure 5), type B consists of moderate numbers of NCI and
minimal or absent DN and Type C have a predominance of elon-
gated and minimal to absent NCI. Finally, type D refers to the
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FIGURE 5 | Frontotemporal lobar degeneration–TDP
neuropathology of patient with progranulin gene mutation.
(A) Neuronal cytoplasmatic inclusion (NCI) in the hippocampus (arrow ).
(B) Superﬁcial frontal neocortex showing NCIs (arrow ) and dystrophic
neurites (DN; arrowhead ). (C) Superﬁcial parietal neocortex showing
NCIs, DN, and neuronal intranuclear inclusions (NII; arrow ). (D) NCI in
frontal cortex. (E,F) Lentiform and round NII in frontal cortex.
Magniﬁcation, 400×.
pathology associated to inclusion body myopathy with Paget’s dis-
ease of bone and frontotemporal dementia caused by CHMP2B
VCP gene mutations, and is characterized by numerous short DN
and frequent lentiform NII. There is good association between
FTLD–TDP types and clinical syndromes (see below).
FTLD–FUS
Fused in sarcoma is a ubiquitously expressed protein that binds
to RNA and DNA and is involved in diverse cellular processes
(Neumann et al., 2009). Given the fact that Both TDP-43 and FUS
are ubiquitously expressed DNA/RNA-binding proteins involved
in multiple aspects of gene expression, transcription regulation,
RNA splicing, transport and translation, although its precise func-
tion is poorly characterized. The understanding of the mecha-
nisms underlying the pathophysiology of FUS accumulation and
FUS-mediated neurodegeneration is still limited. As for TDP-
43 proteinopathies, a toxic gain-of-function mechanism, a loss-
of-function mechanism by depletion of physiological FUS and
maybe co-sequestration of other vital factors, or both, is pos-
sible (Mackenzie et al., 2010b). This recently described FTLD
category is pathological characterized by the presence of NCI
and NII that are strongly immunoreactive for FUS protein and
negative for the other proteins associated to neurodegenerative
dementias (Neumann et al., 2009). Another consistent and strik-
ing feature of this group is the severe atrophy of the head of caudate
nucleus (Roeber et al., 2008) that can be a useful clinical predic-
tor of this pathology when detected by neuroimaging (Josephs
et al., 2010). The true incidence and prevalence of FTLD–FUS
is unknown. Based on brain bank studies has an estimate fre-
quency of approximately 5% of all FTLD patients (Mackenzie
et al., 2011b).
CLINICO-PATHOLOGICAL CORRELATIONS
The recent discoveries onFTLDpathologies and their classiﬁcation
according to themajor protein deposited in brain allowed to estab-
lished associations between the FTLD pathologies and the clinical
syndromes. In this section we will described the most impor-
tant clinico-pathological associations taking as starting point the
clinical syndrome and genetic variability.
The syndrome bvFTD, the most common clinical syndrome
in FTLD spectrum, is histopathologically heterogeneous (Josephs
et al., 2011; Rohrer et al., 2011),with half of the patients having tau
pathology and the other 50% have tau-negative FTLD with ubiq-
uitin immunoreactive inclusions (FTLD-U),which in themajority
of cases are TPD-43 positive (Hodges et al., 2004; Snowden et al.,
2007). In the FTLD-tau group presenting with bvFTD, Pick’s dis-
ease account for the majority of the cases (∼70%) followed by
CBD and a minority of cases have PSP pathology (Wadia and
Lang, 2007; Ling et al., 2010; Josephs et al., 2011). It should keep
in mind that classical PSP clinical presentation, recently referred
as Richardson syndrome, permit accurate ante-mortem diagnosis
in most cases (Josephs and Dickson, 2003). The atypical clinical
presentations, which can fall under the umbrella of FTLD, reﬂect
varying anatomical distribution of tau pathology. In the FTLD–
TDPgroup,bvFTD isnot strongly associated to anyTDPparticular
type (Josephs et al., 2011). A subtype of bvFTD characterized by
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a very young onset patient (∼40 years), with a clinical syndrome
dominated by hypersexual and hyperphagic behavior, prominent
stereotypy, and obsessionality, together with striatal atrophy was
tightly associated to FTLD–FUS (Roeber et al., 2008; Urwin et al.,
2010; Snowden et al., 2011).
The phenotype FTD–MND is highly speciﬁc of FTLD–TDP
pathology (Josephs et al., 2011; Rohrer et al., 2011), with type
B being the most common (Mackenzie et al., 2011a). The asso-
ciated neuropathology of patients with mutations on C9ORF72
gene is also a FTLD–TDP type B (Stewart et al., 2012). Interest-
ingly, this subset of patients (MND/ALS and FTLD–TDP with
C9ORF72 repeat expansion) have also p62 positive, TDP-43 neg-
ative, neuronal cytoplasmic, and intranuclear inclusions in the
cerebellum and hippocampus that seems to be speciﬁc for this
condition (Al-Sarraj et al., 2011).
Progressive non-ﬂuent aphasia is associated predominantly
with FTLD–tau (70%; Josephs et al., 2011) and no particular asso-
ciation with speciﬁc tau pathology can be made (i.e., PiD, CBD,
or PSP).
Semantic dementia is predominantly associated to FTLD–TDP
(83%),particularly typeC (Josephs et al., 2011;Rohrer et al., 2011).
Although clinically heterogeneous, even among family mem-
bers carrying the same mutation, certain characteristics have
been linked more frequently to FTLD patients with progranulin
mutations, such extrapyramidal features and parietal lobe deﬁcits
(Rohrer et al., 2008; van Swieten and Heutink, 2008; Taipa et al.,
2012).
In summary, FTLD is the umbrella term for a heteroge-
neous group of clinical (bvFTD, PNFA, SD, FTD–MND) and
pathological disorders (FTLD–tau, FTLD–TDP, and FTLD–FUS),
with strong clinico-pathological associations in certain groups
(i.e., FTD–MND/FTLD–TDP, SD/FTLD–TDP, PNFA–FTLD–tau,
young onset bvFTD/FTLD–FUS).
CONCLUSION
The precise mechanisms involved in neurodegeneration remain
largely unknown, but some proteins have emerged as important
players in the mechanism of neurodegeneration. This suggests, at
least partially and probably early in the process, speciﬁc patho-
physiological characteristics in the different neurodegenerative
dementias. Consequently, the rational use of disease modifying
treatments will almost certainly imply a speciﬁc diagnosis at a
molecular level. This brings an outstanding challenge to clinicians
due to heterogeneous clinical presentations with the same mol-
ecular pathology. Clinico-pathological studies helped in reﬁning
diagnosis and continue to be essential in order to pursuit in vivo
biomarkers to achieve higher diagnostic speciﬁcity. Adding to the
clinical overlap of distinct neuropathological diagnosis, it must
be taken into account that while evaluating post-mortem brains,
pathologists have to assess numerous pathologies, keeping inmind
the clinical presentation, but also to be aware of the frequent ﬁnd-
ings of comorbidity or unexpected pathologies which characterize
the aging brain (Alafuzoff et al., 2009).
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